AmbioPharm, a U.S.-based pharmaceutical services company, has announced the groundbreaking of a $28 million expansion at its Shanghai site. The project, set to add 70,000 square feet of manufacturing capacity, is designed to meet growing global demand for peptide therapeutics.
AmbioPharm, Contract Manufacturing & Development (CDMO) Profile AmbioPharm is a full service peptide CDMO. We manufacture research & cGMP #peptides at small & large scales, perform pilot manufacturing, & process development. AmbioPharm, Inc. (APi) has developed a new business model
AmbioPharm is a Manufacturer/Innovator company operating in the pharmaceutical industry. AmbioPharm is a leading, innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. AmbioPharm produces custom products and services for research, clinical development, and commercial application
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
